RFL

RafaelF

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$2.10

Analysis reference price unavailable

Analysis 2026-05-07 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$1.20

Analysis reference price unavailable

Analysis 2026-05-07 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$0.70

Analysis reference price unavailable

Analysis 2026-05-07 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-05-07

AI commentary

Primary-source evidence is real, but the setup remains a low-coverage monitoring story rather than a broadening fundamental recovery. The April 22, 2026 company release sharpened focus on Q3 2026 NPC1 data and added a longer-horizon MIT licensing watch item, while the March 16, 2026 10-Q reinforced that investors still need to watch liquidity and trial-spend pace closely [#8-K-2026-04-22][#10-Q-2026-03-16]. Recent trusted-news and analyst-revision evidence were unavailable in the packet, which lowers conviction rather than supporting a stronger bullish read.

RankAlpha Sentiment Codex - 2026-05-07

Open full AI memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-08-31eventRunway and financing scrutiny should rise as trial spend continuesHigh impact

The January 31, 2026 10-Q reported cash and cash equivalents of about $37.8 million versus $52.8 million at July 31, 2025, with six-month operating cash use of about $14.3 million and elevated prepaid clinical costs, so investors are likely to keep testing whether existing liquidity comfortably bridges the company through its pivotal readout without added capital [#10-Q-2026-03-16].

2026-09-30eventPhase 3 TransportNPC topline remains the core value inflectionHigh impact

Management said Phase 3 results from TransportNPC are due in calendar Q3 2026, keeping the stock centered on a binary NPC1 data event rather than near-term operating execution. A positive readout could materially re-rate the lead asset, while a miss would likely impair the current thesis [#8-K-2026-04-22].

2027-04-30catalystMIT Alzheimer license creates a longer-horizon licensing and program-expansion watch itemHigh impact

Rafael disclosed an exclusive MIT license covering cyclodextrin use in ApoE4-positive Alzheimer's disease, which gives the company a defined partnership and intellectual-property path beyond the NPC1 program. The catalyst is still low-probability and long-dated because the packet does not show a funded clinical timeline, partner economics, or regulatory plan for this indication [#8-K-2026-04-22].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-07 • Updated nightlySource: Internal modelMethodology